Published: 2018-06-22

Bioequivalence of two quinidine gluconate 324mg extended release formulations in healthy Brazilian volunteers under fed conditions: a pilot study

Luciana Ferrara, Srinivas G.


Background: Quinidine is an antimalarial schizonticide and an antiarrhythmic agent with Class Ia activity. The present study was aimed at analyzing the bioequivalence of the proposed generic product Quinidine Gluconate 324mg Extended Release Tablets with the marketed product of Sun pharmaceuticals, USA.

Methods: The design was an open, longitudinal, randomized, comparative study of two formulations in single dose of 324 mg, with a 5 days washout in between doses. The study was conducted in 12 healthy adult male and female Brazilian volunteers under fed conditions in Azidus Brasil, Valinhos, Brazil. Blood samples were collected post dose up to 36 hours for pharmacokinetic analysis and safety evaluation was done by assessing the adverse events and laboratory tests. A validated LC-MS/MS method was used to determine the plasma concentrations of Quinidine. Bioequivalence between the products was established by calculating 90% confidence intervals (90% CI) for the ratio of Cmax, AUC0-t and AUC0-∞ values for the proposed generic product and marketed product.

Results: The 90% confidence intervals found for the relation Test/Reference, were Cmax 80.78% to 109.07%, AUC0-t 86.04% to 104.24% and AUC0-∞ 86.25% to 104.71%. There were no clinically relevant changes in the vital parameters and the QT, QTc were not adversely affected and both the drug products were found to be safe and tolerable at the given strength.

Conclusions: According to FDA´s guidelines for Bioequivalence research, the confidence intervals for Cmax, AUC0-t and AUC0-∞ ranged between 80.00-125.00%. The above limits obtained were within the accepted bio-equivalence limits.


Bioequivalence, Safety, Quinidine gluconate

Full Text:



Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990 Oct 1;82(4):1106-16.

Ochs HR, Greenblatt DJ, Woo E, Franke K, Pfeifer HJ, Smith TW. Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. American Journal of Cardiology. 1978 Apr 1;41(4):770-7.

Miller KD, Greenberg AE, Campbell CC. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. New England Journal of Medicine. 1989 Jul 13;321(2):65-70.

Prescribing information of Quinidine gluconate ER tablets of Mutual Pharmaceutical Company, INC. Available at: Accessed on Feb 2010

World Medical Association Declaration of Helsinki. Ethical principles for the medical research involving human volunteers adopted by the: 59th General Assembly Seoul, Korea. 2008. Available at: Accessed on Oct 2013.

ICH Expert Working Group. Guideline for Good Clinical Practice E6 (R1): International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. J Postgrad Med. 1996;47:45-50.

Perry R. Perspectives on the bioequivalence and therapeutic equivalence of generic formulations: An overview of the landscape. Clin Ther. 2010;32:1796-7.

Chen ML, Shah V, Patnaik R, Adams W, Hussain A, Conner D, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharmaceutical research. 2001 Dec 1;18(12):1645-50.

Food and Drugs Administration. Guidance for industry Statistical Approaches to Establishing Bioequivalence. 2009. Available at: Accessed on Jan 31, 2001.

The European Agency for the Evaluation of Medicinal Products EMA. Committee for Proprietary Medicinal Products (CPMP) Note for guidance on the investigation of Bioavailability and Bioequivalence, London. 2001. Available at: Accessed on Jan 20, 2010